Format

Send to

Choose Destination
Arch Pediatr Adolesc Med. 2003 Jul;157(7):661-4.

Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children.

Author information

1
Division of Gastroenterology, Department of Pediatrics, University of Iowa, Iowa City 52242, USA. Dinesh-Pashankar@uiowa.edu

Abstract

OBJECTIVES:

To assess the clinical and biochemical safety profile of long-term polyethylene glycol 3350 (PEG) therapy in children with chronic constipation and to assess pediatric patient acceptance of PEG therapy.

DESIGN:

Prospective observational study.

SETTING:

Pediatric clinics at a referral center. Patients Eighty-three children (44 with chronic constipation, 39 with constipation and encopresis) receiving PEG therapy for more than 3 months.

MAIN OUTCOME MEASURES:

Clinical adverse effects related to PEG therapy and acceptance and compliance with PEG therapy. Serum electrolyte levels, osmolality, albumin levels, and liver and renal function test results were measured.

RESULTS:

At the time of evaluation, the mean duration of PEG therapy was 8.7 months, and the mean PEG dose was 0.75 g/kg daily. There were no major clinical adverse effects. All blood test results were normal, except for transient minimal alanine aminotransferase elevation unrelated to therapy in 9 patients. All children preferred PEG to previously used laxatives, and daily compliance was measured as good in 90% of children.

CONCLUSIONS:

Long-term PEG therapy is safe and is well accepted by children with chronic constipation with and without encopresis.

PMID:
12860787
DOI:
10.1001/archpedi.157.7.661
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center